Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to -$187000.0.

  • Metagenomi's Cash from Financing Activities rose 6199.19% to -$187000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$430000.0, marking a year-over-year decrease of 10052.01%. This contributed to the annual value of $84.0 million for FY2024, which is 820167.98% up from last year.
  • Per Metagenomi's latest filing, its Cash from Financing Activities stood at -$187000.0 for Q3 2025, which was up 6199.19% from -$166000.0 recorded in Q2 2025.
  • Metagenomi's 5-year Cash from Financing Activities high stood at $86.5 million for Q1 2024, and its period low was -$2.0 million during Q2 2024.
  • In the last 3 years, Metagenomi's Cash from Financing Activities had a median value of -$176500.0 in 2025 and averaged $8.5 million.
  • Within the past 5 years, the most significant YoY rise in Metagenomi's Cash from Financing Activities was 191483.12% (2024), while the steepest drop was 511025.64% (2024).
  • Metagenomi's Cash from Financing Activities (Quarter) stood at -$1.3 million in 2023, then soared by 63.12% to -$492000.0 in 2024, then soared by 61.99% to -$187000.0 in 2025.
  • Its last three reported values are -$187000.0 in Q3 2025, -$166000.0 for Q2 2025, and -$77000.0 during Q1 2025.